These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 30060279)

  • 21. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice.
    Cho MS; Park DW
    Korean J Intern Med; 2017 Sep; 32(5):769-779. PubMed ID: 28823143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Tada T; King LA; Kastrati A
    Eur Heart J; 2012 Dec; 33(24):3078-87. PubMed ID: 23091199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perioperative management of dual anti-platelet therapy.
    Webster TD; Vaishnava P; Eagle KA
    Hosp Pract (1995); 2016 Dec; 44(5):237-241. PubMed ID: 27846735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials.
    Verdoia M; Schaffer A; Barbieri L; Montalescot G; Collet JP; Colombo A; Suryapranata H; De Luca G
    Angiology; 2016 Mar; 67(3):224-38. PubMed ID: 26069031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
    Barillà F; Pelliccia F; Borzi M; Camici P; Cas LD; Di Biase M; Indolfi C; Mercuro G; Montemurro V; Padeletti L; Filardi PP; Vizza CD; Romeo F;
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18(1):1-9. PubMed ID: 27635937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: A meta-analysis of 11 randomized trials.
    Verdoia M; Khedi E; Ceccon C; Suryapranata H; De Luca G
    Int J Cardiol; 2018 Aug; 264():30-38. PubMed ID: 29776573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Optimal duration of dual antiplatelet therapy after coronary stent placement or acute coronary syndrome. Is customisation possible?].
    Georges JL; Cherif G; Ajlani B
    Ann Cardiol Angeiol (Paris); 2019 Nov; 68(5):347-357. PubMed ID: 31471043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral dual antiplatelet therapy: what have we learnt from recent trials?
    Montalescot G; Sabatine MS
    Eur Heart J; 2016 Jan; 37(4):344-52. PubMed ID: 26248569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?].
    Darius H
    Internist (Berl); 2021 Nov; 62(11):1243-1252. PubMed ID: 34633479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of six versus 12 months of dual antiplatelet therapy in patients with drug-eluting stent implantation after risk stratification with the residual SYNTAX score: Results from a secondary analysis of the I-LOVE-IT 2 trial.
    Qiu M; Li Y; Li J; Xu K; Jing Q; Dong S; Jin Z; Zhao P; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):565-573. PubMed ID: 28211603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy.
    Kereiakes DJ; Yeh RW; Massaro JM; Driscoll-Shempp P; Cutlip DE; Steg PG; Gershlick AH; Darius H; Meredith IT; Ormiston J; Tanguay JF; Windecker S; Garratt KN; Kandzari DE; Lee DP; Simon DI; Iancu AC; Trebacz J; Mauri L;
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1552-62. PubMed ID: 26493248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
    Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
    Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation after coronary interventions].
    Schäfer A; Bauersachs J
    Herz; 2019 Jun; 44(4):365-378. PubMed ID: 31087108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
    Garg P; Galper BZ; Cohen DJ; Yeh RW; Mauri L
    Am Heart J; 2015 Feb; 169(2):222-233.e5. PubMed ID: 25641531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
    Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.
    Kereiakes DJ; Yeh RW; Massaro JM; Cutlip DE; Steg PG; Wiviott SD; Mauri L;
    J Am Coll Cardiol; 2016 May; 67(21):2492-502. PubMed ID: 27046159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain).
    Ribera A; Ferreira-Gonzalez I; Marsal JR; Oristrell G; Faixedas MT; Rosas A; Tizón-Marcos H; Rojas S; Labata C; Cardenas M; Homs S; Tomas-Querol C; Garcia-Picart J; Gomez-Hospital JA; Pijoan JI; Masotti M; Mauri J; Garcia Dorado D;
    BMJ Open; 2019 Jul; 9(7):e028114. PubMed ID: 31340964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation.
    Chen H; Power D; Giustino G
    Expert Rev Cardiovasc Ther; 2018 Oct; 16(10):735-748. PubMed ID: 30221557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.